Literature DB >> 12115944

Spinal muscular atrophy: recent advances and future prospects.

Sophie Nicole1, Carmen Cifuentes Diaz, Tony Frugier, Judith Melki.   

Abstract

Spinal muscular atrophies (SMA) are characterized by degeneration of lower motor neurons associated with muscle paralysis and atrophy. Childhood SMA is a frequent recessive autosomal disorder and represents one of the most common genetic causes of death in childhood. Mutations of the SMN1 gene are responsible for SMA. The knowledge of the genetic basis of SMA, a better understanding of SMN function, and the recent generation of SMA mouse models represent major advances in the field of SMA. These are starting points towards understanding the pathophysiology of SMA and developing therapeutic strategies for this devastating neurodegenerative disease, for which no curative treatment is known so far. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115944     DOI: 10.1002/mus.10110

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  21 in total

1.  Spinal muscle atrophy type 1 (Werdnig-Hoffman disease) with complex cardiac malformation.

Authors:  Wael El-Matary; Sunanda Kotagiri; Duncan Cameron; Ian Peart
Journal:  Eur J Pediatr       Date:  2004-06       Impact factor: 3.183

Review 2.  Targeting RNA-splicing for SMA treatment.

Authors:  Jianhua Zhou; Xuexiu Zheng; Haihong Shen
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

3.  Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons.

Authors:  Honglai Zhang; Lei Xing; Wilfried Rossoll; Hynek Wichterle; Robert H Singer; Gary J Bassell
Journal:  J Neurosci       Date:  2006-08-16       Impact factor: 6.167

4.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

5.  Compensatory axon sprouting for very slow axonal die-back in a transgenic model of spinal muscular atrophy type III.

Authors:  Esther Udina; Charles T Putman; Luke R Harris; Neil Tyreman; Victoria E Cook; Tessa Gordon
Journal:  J Physiol       Date:  2017-01-25       Impact factor: 5.182

6.  Perceptions of equine-assisted activities and therapies by parents and children with spinal muscular atrophy.

Authors:  Danielle Lemke; Erin Rothwell; Tara M Newcomb; Kathryn J Swoboda
Journal:  Pediatr Phys Ther       Date:  2014       Impact factor: 3.049

Review 7.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

8.  DNA Damage Response and DNA Repair in Skeletal Myocytes From a Mouse Model of Spinal Muscular Atrophy.

Authors:  Saniya Fayzullina; Lee J Martin
Journal:  J Neuropathol Exp Neurol       Date:  2016-07-24       Impact factor: 3.685

9.  Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes.

Authors:  Wilfried Rossoll; Gary J Bassell
Journal:  Results Probl Cell Differ       Date:  2009

Review 10.  Mechanobiology of embryonic skeletal development: Insights from animal models.

Authors:  Niamh C Nowlan; James Sharpe; Karen A Roddy; Patrick J Prendergast; Paula Murphy
Journal:  Birth Defects Res C Embryo Today       Date:  2010-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.